Waltham Research Center Recruiting Migraine Patients Ages 12-17

WALTHAM, MA — MedVadis Research in Waltham is actively recruiting migraine patients ages 12-17 for a new clinical research study evaluating the safety and effectiveness of an investigational migraine treatment in adolescents.

The World Health Organization classifies migraine as one of the 10 most disabling medical illnesses and occurs in approximately four to 11 percent of elementary school-aged children and eight to 15 percent of high school-aged adolescents.

This multicenter, placebo controlled, Phase 3 clinical trial is studying rimegepant as an investigational acute treatment. Rimegepant is approved by the U.S. Food and Drug Administration (FDA) to treat and prevent episodic migraine in adults and marketed as Nurtec ODT.

“Migraine can be debilitating in adolescents, but often goes undiagnosed because they have a more difficult time understanding and expressing their pain,” said Egilius L.H. Spierings, M.D., Ph.D., neurologist and researcher at MedVadis Research, in a statement. “Limited treatment options for migraine are available for adolescents today. Rimegepant has shown effectiveness as an acute treatment in adults with migraine, and we are hopeful it will also help adolescents get relief and return more quickly to their daily life.”

Clinicians at MedVadis Research are now seeking eligible participants for the study. To enroll, participants must be between age 12 and 17, have at least one migraine per month, and have at least a six-month history of migraine. For more information about participating in the study, call 781-373-2940 or visit https://medvadis.com/pediatric-migraine-study.